Spero Therapeutics (NASDAQ:SPRO) Insider Esther Rajavelu Sells 40,851 Shares of Company Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) insider Esther Rajavelu sold 40,851 shares of the company’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $1.04, for a total transaction of $42,485.04. Following the transaction, the insider owned 946,000 shares in the company, valued at $983,840. The trade was a 4.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Spero Therapeutics Stock Down 5.6%

SPRO stock opened at $1.01 on Wednesday. The firm has a market cap of $58.82 million, a price-to-earnings ratio of 9.18 and a beta of 1.59. Spero Therapeutics, Inc. has a twelve month low of $0.96 and a twelve month high of $3.08. The business’s fifty day simple moving average is $1.15 and its two-hundred day simple moving average is $1.93.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%. Research analysts expect that Spero Therapeutics, Inc. will post -0.97 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SPRO. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Spero Therapeutics during the second quarter worth $36,000. Global Retirement Partners LLC purchased a new stake in Spero Therapeutics during the 2nd quarter valued at about $55,000. GSA Capital Partners LLP purchased a new stake in Spero Therapeutics during the 2nd quarter valued at about $632,000. BlackRock Inc. acquired a new position in shares of Spero Therapeutics in the second quarter valued at about $1,314,000. Finally, Alphabet Inc. purchased a new stake in Spero Therapeutics in the second quarter valued at approximately $1,967,000. Institutional investors and hedge funds own 25.60% of the company’s stock.

Analysts Set New Price Targets

SPRO has been the subject of several recent analyst reports. Zacks Research upgraded shares of Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. Weiss Ratings raised Spero Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday. Cantor Fitzgerald started coverage on Spero Therapeutics in a report on Wednesday, October 28th. They set an “overweight” rating and a $6.00 price objective for the company. Compass Point raised Spero Therapeutics to a “neutral” rating in a research report on Monday, September 14th. Finally, HC Wainwright boosted their target price on Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Monday, September 14th. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Spero Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $6.00.

About Spero Therapeutics

Spero Therapeutics, Inc. (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.